FBRX - NASDAQ

Forte Biosciences, Inc.

Forte Biosciences, Inc.

FBRX·NASDAQ

$16.69

-8.2%
HealthcareBiotechnology

Forte Biosciences, Inc. operates as a clinical-stage biopharmaceutical company in the United States. It is developing FB-102 program that addresses various autoimmune diseases, such as vitiligo and alopecia areata. The company is headquartered in Dallas, Texas.

StatementsValue Model

At a Glance

Live Snapshot
Market Cap$231.75M
EPS-4.7100
P/E Ratio-3.54
Earnings Date08/13/2026

FBRX

Preferred Stock

Last Annual Value

0.00

3-Year CAGR

%

5-Year CAGR

%

10-Year CAGR

%

Failed to load chart data

Forte Biosciences, Inc.

Forte Biosciences, Inc. Competitors Analysis of preferred-stock

FBRX · NASDAQ
Companypreferred-stock
CAGR 3Y
CAGR 5Y
CAGR 10Y

No comparison data available

We couldn't find preferred-stock data for this stock's competitors.

Forte Biosciences, Inc.

Forte Biosciences, Inc. Fair Value Envelope

FBRX · NASDAQ

Our analysis suggests that FBRX has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $16.69, this represents a potential HIDDEN relative to our calculated worth for Forte Biosciences, Inc..

HIDDEN
Intrinsic Value
Current Price: $16.69

Related Guides

Blog Categories

Continue your FBRX research with focused valuation guides.

Fundamentals

Decode statement quality and operating durability.

Accounting

Interpret line items with cleaner analytical framing.

Forecasting

Translate historical performance into forward scenarios.

Reference

Use practical frameworks for statement-led valuation.

Research Paths

Pick your next lens
1

Snapshot

Start with context, operating signals, and key market metrics.

2

Value Model

Stress test fair value across bear, base, and bull assumptions.

3

Statements

Validate revenue quality, margins, and balance sheet durability.

4

Earnings Call

Read management commentary and compare it with reported outcomes.

5

Dividends

Check payout sustainability and long-term distribution behavior.

6

Analyst Expectations

Review consensus spread and where estimate risk is concentrated.